Caren van Roekel

132 Chapter 4 REFERENCES 1. Elschot M, Nijsen JF, Lam MG, Smits ML, Prince JF, Viergever MA, et al. ((9)(9)m) Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Im. 2014;41(10):1965- 75. Epub 2014/05/14. 2. Braat A, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch M, Lam M. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. Eur Radiol. 2018;28(3):920-8. Epub 2017/08/09. 3. Smits MLJ, Dassen MG, Prince JF, Braat A, Beijst C, Bruijnen RCG, et al. The superior predictive value of ( 166 ) Ho-scout compared with (99m)Tc- macroaggregated albumin prior to ( 166 ) Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Im. 2019. Epub 2019/08/11. 4. Li MD, Chu KF, DePietro A, Wu V, Wehrenberg-Klee E, Zurkiya O, et al. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres. J Vasc Interv Radiol. 2019;30(3):314-9. Epub 2019/03/02. 5. Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, et al. Same-day (90) Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Im. 2016;43(13):2353-9. Epub 2016/11/05. 6. Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session y ttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol. 2014;25(2):266-70. Epub 2013/12/18. 7. Prince JF, van den Bosch M, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, et al. Efficacy of Radioembolization with ( 166 )Ho- Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med. 2018;59(4):582-8. Epub 2017/09/17. 8. Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025-34. 9. Braat A, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, et al. Additional hepatic ( 166 )Ho- radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non- comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol. 2018;18(1):84. Epub 2018/06/16.